0001867096-23-000097.txt : 20230607 0001867096-23-000097.hdr.sgml : 20230607 20230607165804 ACCESSION NUMBER: 0001867096-23-000097 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230607 FILED AS OF DATE: 20230607 DATE AS OF CHANGE: 20230607 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: HALKUFF DAWN CENTRAL INDEX KEY: 0001743658 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40880 FILM NUMBER: 23999679 MAIL ADDRESS: STREET 1: C/O XERIS PHARMACEUTICALS STREET 2: 180 N. LASALLE ST., STE. 1800 CITY: CHICAGO STATE: IL ZIP: 60601 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Xeris Biopharma Holdings, Inc. CENTRAL INDEX KEY: 0001867096 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 180 N. LASALLE STREET, SUITE 1600 CITY: CHICAGO STATE: IL ZIP: 60601 BUSINESS PHONE: 844-445-5704 MAIL ADDRESS: STREET 1: 180 N. LASALLE STREET, SUITE 1600 CITY: CHICAGO STATE: IL ZIP: 60601 4 1 wk-form4_1686171475.xml FORM 4 X0407 4 2023-06-07 0 0001867096 Xeris Biopharma Holdings, Inc. XERS 0001743658 HALKUFF DAWN C/O XERIS BIOPHARMA HOLDINGS, INC. 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607 1 0 0 0 0 Common Stock 2023-06-07 4 A 0 42500 0 A 57500 D These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 7, 2024 or the date of the Company's next annual meeting of stockholders. /s/ Beth Hecht as Attorney-in-Fact 2023-06-07